Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 6/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30449743 | 0.85 | GSK3B (0.56) | POLBGSK3BHPGDRXFP1L3MBTL1 | |
| SCHEMBL2714790 | 0.84 | KDM4E (0.61) | JAK1POLBABL1GSK3BHPGD | |
| SCHEMBL1788016 | 0.80 | KDM4E (0.47) | POLBNPC1RAB9ARXFP1KDM4E | |
| SCHEMBL28129515 | 0.79 | KDM4E (0.44) | JAK1L3MBTL1KDM4EMAPTTSHR | |
| SCHEMBL29155745 | 0.79 | POLB (0.64) | JAK1HSD17B10POLBNPC1RAB9A | |
| SCHEMBL4550418 | 0.79 | ADORA1 (0.45) | JAK1POLBABL1GSK3BHPGD | |
| SCHEMBL22186405 | 0.78 | KDM4E (0.58) | JAK1NPC1RAB9AABL1GSK3B | |
| SCHEMBL28606159 | 0.78 | ALDH1A1 (0.51) | HSD17B10NPC1RAB9AHPGDALDH1A1 | |
| SCHEMBL23064275 | 0.77 | HSD17B10 (0.56) | JAK1HSD17B10GSK3BALDH1A1KDM4E | |
| SCHEMBL2713731 | 0.77 | HSD17B10 (0.49) | JAK1HSD17B10NPC1HSP90AA1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12110287-B2 | Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers | RAQUALIA PHARMA INC. (JP) | 2024-10-08 | — | — | US | disclosed |
| CN-110612285-B | Amide derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2023-04-04 | — | — | CN | disclosed |
| US-20220048892-A1 | HETEROCYCLIC DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2022-02-17 | — | — | US | disclosed |
| EP-3902544-A1 | HETEROCYCLIC DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RaQualia Pharma Inc. (JP) | 2021-11-03 | — | — | EP | disclosed |
| US-11154544-B2 | Amide derivatives as Nav1.7 and Nav1.8 blockers | RAQUALIA PHARMA INC. (JP) | 2021-10-26 | — | — | US | disclosed |
| CN-113164461-A | Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2021-07-23 | — | — | CN | disclosed |
| EP-3487839-B1 | AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RAQUALIA PHARMA INC (JP) | 2020-12-23 | — | — | EP | disclosed |
| WO-2020138271-A1 | HETEROCYCLIC DERIVATIVES AS Nav1.7 and Nav1.8 BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2020-07-02 | — | — | WO | disclosed |
| CN-106478497-B | Arylamine derivatives as TTX-S blockers | 拉夸里亚创药株式会社 | 2020-05-08 | — | — | CN | disclosed |
| CN-110612285-A | Amide derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2019-12-24 | — | — | CN | disclosed |
| EP-3487839-A1 | AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RaQualia Pharma Inc. (JP) | 2019-05-29 | — | — | EP | disclosed |
| WO-2018235851-A1 | AMIDE DERIVATIVES AS Nav1.7 and Nav1.8 BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2018-12-27 | — | — | WO | disclosed |
| EP-2630122-B1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-9302991-B2 | Arylamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| EP-2630122-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2013-08-28 | — | — | EP | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12110287-B2 | Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers | SCN8A, SCN7A, SCN1A | JAK1 4733/4885HSD17B10 1789/4885POLB 4053/4885 |
| US-11154544-B2 | Amide derivatives as Nav1.7 and Nav1.8 blockers | SCN8A, SCN7A, SCN1A | JAK1 4799/4885HSD17B10 1811/4885POLB 3813/4885 |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN2B, SCN1B, SCN2A | JAK1 4790/4885HSD17B10 2660/4885POLB 4126/4885 |
| US-20220048892-A1 | HETEROCYCLIC DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | SCN8A, SCN7A, SCN1A | JAK1 4733/4885HSD17B10 1789/4885POLB 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.